Roche Concludes Acquisition of LumiraDx's Point of Care Technology

Roche confirmed the finalization of the acquisition of LumiraDx’s Point of Care technology after obtaining all necessary antitrust and regulatory approvals. Roche will now start the complete merging of the company's advanced multi-assay point of care platform and the associated research and development, operational, and commercial locations into its worldwide organization.

By acquiring this, Roche enhances its diagnostics collection with an easy-to-operate system that brings together various immunoassay and clinical chemistry tests on one device, with the possibility to grow into molecular testing in the future. The new solution will enable Roche to broaden its range of services in decentralized patient care, as well as facilitate worldwide availability of prompt and useful diagnostic outcomes.

“Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries,” said Matt Sause, CEO of Roche Diagnostics.

Veronique Ameye, chief executive officer of LumiraDx, added: “We are absolutely delighted to continue our journey as part of Roche Diagnostics. Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community-based healthcare around the world. We look forward to writing the next chapter in our shared efforts to deliver even greater impact for patients.”

Roche declared at the conclusion of 2023 that it had finalized a deal to purchase LumiraDx's Point of Care technology.